Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.45 |
| ▸ | PPARA | Q07869 | 13/20 | 0.45 |
| ▸ | PPARD | Q03181 | 3/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069697 | 0.92 | PPARG (0.41) | PPARGPPARAPPARDPDE10ASCN9A | |
| SCHEMBL7066564 | 0.91 | MMP1 (0.40) | PDE10ASCN9AHTTSMN1; SMN2 | |
| SCHEMBL7066781 | 0.91 | CYP1A2 (0.42) | PDE10ASCN9ASTAT3HTTSMN1; SMN2 | |
| SCHEMBL7069421 | 0.90 | SIRT2 (0.43) | PDE10ASCN9AHTTSMN1; SMN2 | |
| SCHEMBL7068772 | 0.89 | PDE10A (0.42) | PDE10ASCN9AMMEACECPA1 | |
| SCHEMBL7070263 | 0.89 | SCN9A (0.38) | PPARGPPARAPPARDPDE10ASCN9A | |
| SCHEMBL7067698 | 0.88 | TRPV1 (0.43) | PPARGPPARAPDE10ASCN9A | |
| SCHEMBL7068926 | 0.88 | TRPV1 (0.43) | PPARGPPARAPDE10ASCN9A | |
| SCHEMBL7069876 | 0.88 | PPARG (0.43) | PPARGPPARAPPARDPDE10A | |
| SCHEMBL7070375 | 0.88 | PPARA (0.46) | PPARGPPARAPPARDMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.